Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142246 | 0.81 | ATM (0.43) | TSHRCYP3A4MAPK1L3MBTL1CYP19A1 | |
| SCHEMBL219410 | 0.79 | CYP19A1 (0.55) | TSHRCYP3A4CYP19A1KMT2AHTT | |
| SCHEMBL1026447 | 0.79 | CYP19A1 (0.62) | TSHRCYP3A4CYP19A1KMT2AHTT | |
| SCHEMBL22032825 | 0.77 | ALDH1A1 (0.46) | MAPTTSHRCYP3A4MAPK1CYP1A2 | |
| SCHEMBL17160442 | 0.77 | KMT2A (0.47) | MAPTTSHRCYP3A4MAPK1CYP1A2 | |
| SCHEMBL9770753 | 0.77 | TSHR (0.47) | MAPTTSHRCYP3A4MAPK1CYP1A2 | |
| SCHEMBL15720733 | 0.77 | KMT2A (0.47) | MAPTTSHRCYP3A4MAPK1CYP1A2 | |
| SCHEMBL7013637 | 0.77 | CDC25C (0.41) | MAPTTSHRCYP3A4MAPK1CYP1A2 | |
| SCHEMBL7141386 | 0.76 | MAPT (0.47) | MAPTTSHRCYP3A4MAPK1CYP1A2 | |
| SCHEMBL7144548 | 0.76 | CA9 (0.45) | MAPTTSHRCYP3A4MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249888-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024043741-A1 | AUTOTAXIN INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 | 2024-02-29 | — | — | WO | disclosed |
| WO-2024043741-A1 | AUTOTAXIN INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 | 2024-02-29 | — | — | WO | disclosed |
| US-RE47122-E1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA University—Industry Collaboration Foundation (KR) | 2018-11-13 | — | — | US | disclosed |
| EP-2588196-B1 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN INC (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-2947081-B1 | 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-10-18 | — | — | EP | disclosed |
| EP-2588479-B3 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-03-29 | — | — | EP | disclosed |
| EP-2947081-A1 | 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors | Ewha University-Industry Collaboration Foundation (KR) | 2015-11-25 | — | — | EP | disclosed |
| EP-2588479-B1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | UNIV EWHA IND COLLABORATION (KR) | 2015-03-04 | — | — | EP | disclosed |
| EP-2588479-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | Ewha University-Industry Collaboration Foundation (KR) | 2013-05-08 | — | — | EP | disclosed |
| EP-2588196-A2 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | Allergan, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012002680-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003477-A2 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-29 | — | — | US | disclosed |
| US-8080568-B1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | ALK, ACVR1, ACVRL1 | MAPT 1486/4885TSHR 323/4885CYP3A4 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.